Joshua K. Sabari, MD

Zongertinib shows strong tolerance and 70%+ responses in HER2-mutant metastatic NSCLC, with a pivotal Phase III trial versus standard chemo-immunotherapy underway.

Weight-based zanjohber niv dosing guide: adjust for CYP3A inhibitors and use early liver tests to avoid dose reductions.

Broad NGS guides metastatic NSCLC care, spotlights common HER2/ERBB2 variants, and explains when liquid biopsy falls short for targeted therapy.

Zongertinib shows strong tolerability in frontline lung cancer cohort, with mostly mild diarrhea, minimal rash, low ILD, and few dose stops.

New data show zongertinib is well tolerated in frontline lung cancer, with manageable diarrhea, minimal rash, and low ILD risk.

Zongertinib shows 77% frontline responses and 96% disease control, with rapid onset and promising durability versus other HER2 TKIs.

FDA‑approved zongertinib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.

New FDA-approved zongepanib boosts responses in HER2-mutant lung cancer, delivering durable control with fewer side effects than standard chemo.

Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new HER2-targeted treatments.

Panelists discuss the management of treatment-associated interstitial lung disease (ILD) and pneumonitis, emphasizing diagnostic strategies, therapeutic options, and patient monitoring.

Panelists discuss strategies for managing adverse events (AEs) related to antibody-drug conjugates (ADCs), focusing on prevention, early detection, and treatment of these effects.

Panelists discuss second-line treatment options and emerging approaches for HER2-mutated non–-small cell lung cancer (NSCLC), highlighting novel therapies and clinical strategies.

Panelists discuss the role of HER2 mutations in non–-small cell lung cancer (NSCLC), focusing on diagnostic approaches, clinical implications, and targeted treatment strategies.

Panelists discuss the presentation and management of a case involving HER2-mutated metastatic non–-small cell lung cancer (NSCLC), exploring treatment options and clinical decision-making

Panelists discuss the management of metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration in patients with central nervous system (CNS) involvement, focusing on treatment strategies and challenges.

Panelists discuss the management of adverse events (AEs) associated with ROS1 inhibition, emphasizing strategies for prevention, monitoring, and treatment of adverse effects.

Panelists discuss treatment decision-making for metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on targeted therapies and personalized treatment strategies.

Panelists discuss next-generation ROS1 inhibition, highlighting emerging therapies, their mechanisms of action, and potential benefits for patients with ROS1-positive metastatic non–small cell lung cancer.

Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and clinical considerations

Panelists discuss the emerging potential of KRAS inhibition in metastatic cancer treatment, exploring novel therapies and their promise for patients with KRAS-mutated tumors.

Panelists discuss individualized treatment selection for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on targeted therapies and personalized approaches to improve patient outcomes.

Panelists discuss the efficacy and safety of KRAS inhibitors for non–-small cell lung cancer (NSCLC), evaluating clinical trial results and their potential impact on treatment strategies.

Panelists discuss second-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on available therapies and personalized approaches based on patient characteristics.

Panelists discuss first-line treatment decision-making for KRAS-mutated metastatic non–-small cell lung cancer (NSCLC), focusing on the selection of targeted therapies and factors influencing clinical choices.

Panelists discuss the use of RNA-based molecular panels in metastatic non–-small cell lung cancer (NSCLC), highlighting their role in guiding personalized treatment decisions and improving patient outcomes.

Panelists discuss decision-making in metastatic non–-small cell lung cancer (NSCLC) when molecular testing results are delayed, focusing on strategies to optimize treatment while awaiting results.

Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment strategies.

Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them with second-line topotecan and CAV regimens, while discussing the potential of various compounds for platinum-sensitive vs platinum-resistant subgroups. He also considers the applicability of TIGIT immunotherapy, highlighting the need for robust clinical trial data on its safety and efficacy as both monotherapy and in combination, and he reflects on whether tiragolumab is more suited for chemotherapy-naive non–small cell lung cancer than for ES-SCLC, based on the phase 2 CITYSCAPE trial results.

Joshua K. Sabari, MD, discusses the antitumor activity of second-line lurbinectedin, noting an ORR of 45%, a median DOR of 6.2 months, and a median OS of 11.2 months in patients with relapsed SCLC, and emphasizes the need for further studies to validate these findings in those with longer chemotherapy-free intervals while considering factors that may lead to lurbinectedin’s use over chemotherapy in candidates for platinum rechallenge, as well as the potential role of G-CSFs for prophylaxis.

Joshua K. Sabari, MD, describes the mechanism of action of lurbinectedin as a synthetic alkaloid that binds to guanine residues in the minor groove of DNA, forming adducts that disrupt DNA repair mechanisms and promote apoptosis in cancer cells, noting that its action contrasts with traditional alkylating agents by specifically interfering with DNA-protein interactions and transcription processes.